Lack of correlation between cisplatin cytotoxic effect and potential Na, K-adenosine triphosphatase (Na, K-ATPase) activity or intracellular level of glutathione

Oncology Reports

Volumn 4, Issue 4, 1997, Pages 833-838

  Ho, Chi Kuan ^a   Yu, Ken Jen ^a,b   Wang, Sheng Yuan ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cisplatin; Glutathione; Na+ K+ ATPase; Ouabain

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CISPLATIN; GLUTATHIONE; OUABAIN;

ACUTE KIDNEY TUBULE NECROSIS; ANTIGEN ANTIBODY COMPLEX; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; NEPHROTOXICITY; PHENOTYPE; PRIORITY JOURNAL; REGRESSION ANALYSIS; TESTIS CANCER;

EID: 0030851625     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.4.4.833     Document Type: Article

References (32)

1. Hoff DDV, Schilsky R, Reichert CM, Reddick RL, Rozencweig M, Young RC and Muggia FM: Toxic effects of cis-dichlorodiammineplatinum (II) in man. Cancer Treatment Rep 63: 1527-1531, 1979.
2. Lippman AJ, Chlson C, Helson L and Krakoff IH: Clinical trials of cis-diamminedichloroplatinum (NSC-119875). Cancer Chemother Rep 57: 191-200, 1973.
3. Gately DP and Howell SB: Cellular accumulation of the anti-cancer agent cisplatin: a review. Br J Cancer 67: 1171-1176, 1993.
4. Chu G: Cellular responses to cisplatin: the roles of DNA-binding proteins and DNA repair. J Biol Chem 269: 787-790, 1994.
5. Scanlon KJ, Kashani-Sabet M, Miyachi H, Lowers LC and Rossi J: Molecular basis of cisplatin resistance in human carcinomas: model systems and patients. Anticancer Res 9: 1301-1312, 1989.
6. Mann SC, Andrews PA and Howell SB: Short-term cis-diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol 25: 236-240, 1990.
7. Schilder R, Hall L, Monks A, Handel L, Fornace A, Ozols R, Fojo A and Hamilton T: Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer 45: 416-422, 1990.
8. Andrews P, Murphy M and Howell S: Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res 45: 6250-6253, 1985.
9. Meister A: Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy (review). Pharmacol Ther 51: 155-194, 1991.
10. +-ATPase. Semin Nephrol 12: 62-66, 1992.
11. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Borek V and Kaye SB: Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 55: 678-684, 1993.
12. +-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum (II) in human ovarian carcinoma cells. Cancer Res 51: 3677-3681, 1991.
13. Bungo M, Fujiwara Y, Kasahara K, Nakagawa K, Ohe Y, Sasaki Y, Irino S and Saijo N: Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum (II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Cancer Res 50: 2549-2553, 1990.
14. Shou JC and Esmann M: The Na, K-ATPase. J Bioenerg Biomembrane 24: 249-261, 1992.
15. Doucet A and Barlet C: Evidence for differences in the sensitivity to ouabain of Na, K-ATPase along the nephrons of rabbit kidney. J Biol Chem 261: 992-995, 1986.
16. +-ATPase activity and cisplatin sensitivity between transformants induced by H-ras and those induced by K-ras. Int J Cancer 58: 672-677, 1994.
17. +-ATPase α-subunit in the lateral wall of rat cochlear duct. J Histochem Cytochem 37: 353-363, 1989.
18. +-ATPase. Prog Nucleic Acid Res Mol Biol 38: 37-89, 1990.
19. Ishikawa T and Ali-Osman F: Glutathione-associated cis-diamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells. J Biol Chem 268: 20116-20125, 1993.
20. Ho CK, Chiang H, Li SY, Yuan CC and Ng HT: Establishment and characterization of a tumorigenic trophoblast-like cell line from a human placenta. Cancer Res 47: 3220-3224, 1987.
21. Mosmann T: A rapid colorimetric assay for cellular growth and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
22. Ash JF, Fineman RM, Kalka T, Morgan M and Wire B: Amplification of sodium- and potassium-activated adenosine-triphosphatase in HeLa cells by ouabain step selection. J Cell Biol 99: 971-983, 1984.
23. Horisberger JD, Lemas V, Kraehenbuhl JP and Rossier BC: Structure-function relationship of Na, K-ATPase. Annu Rev Physiol 53: 565-584, 1991.
24. Lees GJ: Inhibition of sodium-potassium-ATPase: a potentially ubiquitous mechanism contributing to central nervous system neuropathology. Brain Res Rev 16: 283-300, 1991.
25. Deray G, Rieu M, Devynck MA, Pernollet MG, Chanson P, Luton JP and Meyer P: Evidence of an endogenous digitalis-like factor in the plasma of patients with acromegaly. N Engl J Med 316: 575-580, 1987.
26. Doris PA: Regulation of Na, K-ATPase by endogenous ouabain-like materials. Proc Soc Exp Biol Med 205: 202-212, 1994
27. Hamlyn JM and Manunta P: Ouabain, digitalis-like factors and hypertension. J Hypertension 10: S99-S111, 1992.
28. +)-activated ATPase. A biochemical link to digitalis-induced inotropy. Pharmacol Rev 36: 143-163, 1984.
29. Weder AB: Sodium metabolism, hypertension, and diabetes. Am J Med Sci 307: S53-S59, 1994.
30. Ohmori T, Nishio K, Ohta S, Kubota N, Adachi M, Komiya K and Saijo N: Ouabain-resistant non-small cell lung cancer cell line shows collateral sensitivity to cis-diamminedichloroplatinum (II) (CDDP). Int J Cancer 57: 111-116, 1994.
31. Kawai K, Kamatani N, Kuroshima S, Nobori T, Nishioka K, Kamiya H, Sakurai M and Mikanagi K: Cross-resistance to ouabain in a murine leukemia cell variant selected for cis-dichlorodiammineplatinum (II) resistance. Cancer Lett 35: 147-152, 1987.
32. Kelly RA: Endogenous cardiac glycoside like compounds. Hypertension 10: 187-192, 1987.